Emilie Syed

At T-Cypher Bio we generate novel TCR-based therapeutics that have the potential to transform the treatment of immune-mediated disease. Our proprietary platforms provide unique insight into T cell based immunity in both health and disease. High throughput, high-resolution profiling of the immune synapse enables us to map the intracellular target space and profile T cell specificity. These platforms not only give us tools to build highly innovative drugs, but also build immune system data sets of unprecedented size. These data sets support cutting edge computational modelling of T cell repertoires which will revolutionize T cell immunology. To build our oncology pipeline, we validate novel, shared, tumour-specific targets and identify panels of rare functionally-defined T cell clones. The unique TCRs we identify are the foundation of our broad pipeline of lifesaving therapeutics for underserved solid tumour patients.

Spintex is inspired by spiders to spin the next generation of sustainable fibres for fashion and beyond.

Oxford Immune Algorithmics aims to transform health care by responsibly applying traceable Artificial General Intelligence to eradicate disease-related suffering with continuous innovation.

Zinc exists to accelerate Science-for-Impact innovation, partnering with people and organisations to build a better future for people and planet. Through our venture building, talent initiatives and innovation partnerships, we work across the entire Science-for-Impact ecosystem to create the conditions, capabilities, and coalitions needed for transformative change. Pre-seed investment: We back exceptional entrepreneurial talent from the conception of a new Science-for-Impact venture through to seed, providing the funding, venture-building expertise, team building, and coaching required to set teams up for impact on people and planet at scale. Learn more on our website here: https://www.zinc.vc/ To apply for funding, please tell us a bit about yourself and what youre building via this short form: https://airtable.com/appTvgH4eAXwSD2Vs/pagxU4iWkcj9vJrWj/form

Parkwalk is the largest growth EIS fund manager, backing world-changing technologies emerging from the UK’s leading universities and research institutions. As well as its flagship, evergreen Opportunities EIS Fund and Knowledge Intensive EIS Funds, Parkwalk also manages award-winning enterprise and innovation funds for the Universities of Cambridge, Oxford, Bristol and Imperial College. Parkwalk invests in businesses creating solutions to real-world challenges, with IP-protected innovations, across a range of sectors including life sciences, AI, quantum computing, advanced materials, genomics, cleantech, future of mobility, medtech and big data.

Oxford University Innovation Limited is wholly owned by the University of Oxford. The company mission is to be the leading international technology transfer organisation, to transfer technology and expertise from the University of Oxford, to deliver value to all our clients, and to maximise social and economic benefits in a commercial manner. Oxford University Innovation helps staff and students to apply their expertise and research for wider social and economic benefit. Our role is to help University staff and students bring the benefits of their research and expertise to create impact in wider society. We support Oxford’s researchers, staff and students, offering commercial skills and a range of specialist resources in order to maximise research impact.

At T-Cypher Bio we generate novel TCR-based therapeutics that have the potential to transform the treatment of immune-mediated disease. Our proprietary platforms provide unique insight into T cell based immunity in both health and disease. High throughput, high-resolution profiling of the immune synapse enables us to map the intracellular target space and profile T cell specificity. These platforms not only give us tools to build highly innovative drugs, but also build immune system data sets of unprecedented size. These data sets support cutting edge computational modelling of T cell repertoires which will revolutionize T cell immunology. To build our oncology pipeline, we validate novel, shared, tumour-specific targets and identify panels of rare functionally-defined T cell clones. The unique TCRs we identify are the foundation of our broad pipeline of lifesaving therapeutics for underserved solid tumour patients.